An interventional study of hsp90 in Liver Cancer, sponsored by Protgen Ltd. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2014-12-24.
Sponsored by Protgen Ltd · Not applicable, Interventional, and Diagnostic
Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases.
Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases, validate accuracy, specificity and sensitivity of Hsp90α kit.
1,391 studies on the registry are indexed under Liver Neoplasms; 345 are open to participants now.
This study's planned enrollment of 1,100 is above the median of 47 across 968 interventional studies indexed under Liver Neoplasms.
Browse Liver Neoplasms studies →Protgen Ltd is the lead sponsor of 12 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Detect plasma Hsp90α concentration of liver cancer patients
Device: hsp90
Detect plasma Hsp90α concentration of lung cancer patients
Also known as: biomarker
Hsp90α Concentration of plasma
Detect Hsp90α Concentration(ng/ml) of plasma and calculate the accuracy, specificity and sensitivity of Hsp90α kit
Time frame: 4 months
This study is status unknown, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Protgen Ltd